Opinion|Videos|October 16, 2024
Switching patients to JAK Inhibitors in Atopic Dermatitis in Clinical Practice
Key Takeaways
- Dermatologists' comfort with JAK inhibitors is influenced by familiarity and patient-specific factors, affecting their willingness to switch treatments.
- Switching from biologics to JAK inhibitors is determined by treatment response, side effects, and patient preferences.
Medical experts rate dermatologists’ comfort with switching to JAK inhibitors and describe how frequently to switch patients from biologics to JAK inhibitors, including their treatment strategy for this population.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How would you rate dermatologists’ comfort in switching to a JAK inhibitor?
- How often do you have to switch patients from biologics to JAK inhibitors?
- What is your treatment strategy for this patient population?
Advertisement
Related to this article
KT-621, an oral STAT6 degrader, cut mean EASI by 62.6% after 4 weeks with no treatment-related adverse events in a phase 1b atopic dermatitis study.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
Lindsay Ackerman, MD, and Chris Bunick, MD, PhD, examine how ORAL Surveillance shaped JAK warnings and what long-term atopic dermatitis data show.
In a phase 2 decentralized study, once-daily trientine tetrahydrochloride improved convenience and adherence in Wilson disease; 80% preferred it.
Type 2 biologics reduced mucus plugs in asthma trials, and quantitative imaging may help detect this treatable phenotype, according to a GOLD 2026 session.
In adults with late-onset PFIC, odevixibat improved pruritus within 3 months in a real-world study at presented at The Liver Meeting 2026.
CT-detected mucus plugs affect up to 67% of patients with COPD and are linked to worse lung function, exacerbations, and mortality, even without symptoms.
In patients with compensated MASH cirrhosis, Baveno VII and ANTICIPATE-NASH showed moderate agreement with HVPG and underestimated CSPH prevalence.
Advertisement
Advertisement
Trending on HCPLive
1
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
2
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
3
ELSPIRE: Elafibranor Achieves ALP Normalization in 85% With PBC
4
Moving the Needle in Medicine: Mentorship, Teams, and Heart Failure Leadership, With Robert Mentz, MD
5